Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant

Stevens S Smith, Paula A Keller, Kate H Kobinsky, Timothy B Baker, David L Fraser, Terry Bush, Brooke Magnusson, Susan M Zbikowski, Timothy A McAfee, Michael C Fiore, Stevens S Smith, Paula A Keller, Kate H Kobinsky, Timothy B Baker, David L Fraser, Terry Bush, Brooke Magnusson, Susan M Zbikowski, Timothy A McAfee, Michael C Fiore

Abstract

Introduction: Telephone tobacco quitlines are effective and are widely used, with more than 500,000 U.S. callers in 2010. This study investigated the clinical effectiveness and cost-effectiveness of 3 different quitline enhancements: combination nicotine replacement therapy (NRT), longer duration of NRT, and counseling to increase NRT adherence.

Methods: In this study, 987 quitline callers were randomized to a combination of quitline treatments in a 2 × 2 × 2 factorial design: NRT duration (2 vs. 6 weeks), NRT type (nicotine patch only vs. patch plus nicotine gum), and standard 4-call counseling (SC) versus SC plus medication adherence counseling (MAC). The primary outcome was 7-day point-prevalence abstinence (PPA) at 6 months postquit in intention-to-treat (ITT) analyses.

Results: Combination NRT for 6 weeks yielded the highest 6-month PPA rate (51.6%) compared with 2 weeks of nicotine patch (38.4%), odds ratios [OR] = 1.71 (95% confidence interval [CI]:1.20-2.45). A similar result was found for 2 weeks of combination NRT (48.2%), OR = 1.49 (95% CI: 1.04-2.14) but not for 6 weeks of nicotine patch alone (46.2%), OR = 1.38 (95% CI: 0.96-1.97). The MAC intervention effect was nonsignificant. Cost analyses showed that the 2-week combination NRT group had the lowest cost per quit ($442 vs. $464 for 2-week patch only, $505 for 6-week patch only, and $675 for 6-week combination NRT).

Conclusions: Combination NRT for 2 or 6 weeks increased 6-month abstinence rates by 10% and 13%, respectively, over rates produced by 2 weeks of nicotine patch when offered with quitline counseling. A 10% improvement would potentially yield an additional 50,000 quitters annually, assuming 500,000 callers to U.S. quitlines per year.

Trial registration: ClinicalTrials.gov NCT01087905.

Figures

Figure 1.
Figure 1.
CONSORT diagram.

References

    1. Abrams D. B., Graham A. L., Levy D. T., Mabry P. L., Orleans C. T. (2010). Boosting population quits through evidence-based cessation treatment and policy. American Journal of Preventive Medicine, 38(Suppl. 3)S351–S363 doi:10.1016/j.amepre.2009.12.011
    1. Aguinis H. (2004). Regression analysis for categorical moderators New York, NY: Guilford Press;
    1. Alpert H. R., Connolly G. N., Biener L. (2013). A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tobacco Control, 22(1), 32–37 doi:10.1136/tobaccocontrol-2011-050129
    1. Baker T. B., Piper M. E., McCarthy D. E., Bolt D. M., Smith S. S., Kim S. Y., Toll B. A. Transdisciplinary Tobacco Use Research Center (TTURC) Tobacco Dependence Phenotype Workgroup (2007). Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. Nicotine & Tobacco Research, 9(Suppl. 4)S555–S570 doi:10.1080/14622200701673480
    1. Barnes S. A., Larsen M. D., Schroeder D., Hanson A., Decker P. A. (2010). Missing data assumptions and methods in a smoking cessation study. Addiction, 105 431–437 doi:10.1111/j.1360-0443.2009.02809.x
    1. Barry M. B., Saul J., Bailey L. A. (2010). U.S. quitlines at a crossroads: Utilization, budget, and service trends 2005–2010. Special report from the North American Quitline Consortium Retrieved from (accessed October 13, 2011)
    1. Bolt D. M., Piper M. E., Theobald W. E., Baker T. B. (2012). Why two smoking cessation agents work better than one: Role of craving suppression. Journal of Consulting and Clinical Psychology, 80 54–65 doi: 10.1037/a0026366
    1. Carlin-Menter S., Cummings K. M., Celestino P., Hyland A., Mahoney M. C., Willett J., Juster H. R. (2011). Does offering more support calls to smokers influence quit success? Journal of Public Health Management and Practice, 17 E9–E15 doi:10.1097/PHH.0b013e318208e730
    1. Campbell S. L., Lee L., Haugland C., Helgerson S. D., Harwell T. S. (2008). Tobacco quitline use: Enhancing benefit and increasing abstinence. American Journal of Preventive Medicine, 35 386–388 doi:10.1016/j.amepre.2008.06.032
    1. Catz S. L., Jack L. M., McClure J. B., Javitz H. S., Deprey M., Zbikowski S. M., Swan G. E. (2011). Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine & Tobacco Research, 13 361–368 doi:10.1093/ntr/ntr003
    1. Centers for Disease Control and Prevention (CDC) Telephone quitlines: A resource for development, implementation, and evaluation Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Final Edition, September 2004; Retrieved from (accessed December 2, 2011)
    1. Centers for Disease Control (CDC) Best practices for comprehensive tobacco control programs—2007 Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; Retrieved from (accessed October 13 2011)
    1. Cohen J., Cohen P., West S., Aiken L. (2003). Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed). Mahwah, NJ: Erlbaum;
    1. Cummings K. M., Hyland A., Carlin-Menter S., Mahoney M. C., Willett J., Juster H. R. (2011). Costs of giving out free nicotine patches through a telephone quit line. Journal of Public Health Management and Practice, 17 E16–E23 doi:10.1097/PHH.0b013e3182113871
    1. Dickerson D. L., Leeman R. F., Mazure C. M., O’Malley S. S. (2009). The inclusion of women and minorities in smoking cessation clinical trials: A systematic review. American Journal on Addictions, 18 21–28 doi: 10.1080/10550490802408522
    1. Drummond M. F., Sculpher M. J., Torrance G. W., O’Brien B. J., Stoddart G. L. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). New York, NY: Oxford University Press;
    1. Ferguson J., Docherty G., Bauld L., Lewis S., Lorgelly P., Boyd K. A., Coleman T. (2012). Effect of offering different levels of support and free nicotine replacement therapy via an English national telephone quitline: Randomised controlled trial. BMJ, 344 e1696doi:10.1136/bmj.e1696
    1. Fiore M. C., Bailey W. C., Cohen S. J., Dorfman S. F., Goldstein M. G., Gritz E. R., Wewers M. E. (2000). Treating tobacco use and dependence. Clinical practice guideline Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; Retrieved from
    1. Fiore M. C., Jaen C. R., Baker T. B., Bailey W. C., Benowitz N. L., Curry S. J., Wewers M. E. (2008). Treating tobacco use and dependence: 2008 update Clinical practice guideline Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; Retrieved from
    1. Hall S. M., Delucchi K. L., Velicer W. F., Kahler C. W., Ranger-Moore J., Hedeker D., Niaura R. (2001). Statistical analysis of randomized trials in tobacco treatment: Longitudinal designs with dichotomous outcome. Nicotine & Tobacco Research, 3 193–202 doi:10.1080/14622200110050411
    1. Hedeker D., Gibbons R. D. (2006). Longitudinal data analysis Hoboken, NJ: John Wiley & Sons;
    1. Hedeker D., Mermelstein R. J., Demirtas H. (2007). Analysis of binary outcomes with missing data: Missing = smoking, last observation carried forward, and a little multiple imputation. Addiction, 102 1564–1573 doi:10.1111/j.1360-0443.2007.01946.x
    1. Hughes J. R., Peters E. N., Naud S. (2011). Effectiveness of over-the-counter nicotine replacement therapy: A qualitative review of nonrandomized trials. Nicotine & Tobacco Research, 13 512–522 doi:10.1093/ntr/ntr055
    1. Hyland A., Li Q., Bauer J. E., Giovino G. A., Steger C., Cummings K. M. (2004). Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine & Tobacco Research, 6(Suppl. 3)S363–S369 doi:10.1080/14622200412331320761
    1. Jaccard J. J. (2001). Interaction effects in logistic regression Newbury Park, CA: Sage;
    1. Kaufman A., Augustson E., Finney-Rutten L., Davis K. (2010). Awareness and use of tobacco quitlines: Evidence from the Health Information National Trends Survey. Journal of Health Communication, 15(Suppl. 3)264–278 doi:10.1080/10810730.2010.526172
    1. Kraemer H. C., Wilson G. T., Fairburn C. G., Agras W. S. (2002). Mediators and moderators of treatment effects in randomized clinical trials. Archives of General Psychiatry, 59 877–883 doi:10.1001/archpsyc.59.10.877
    1. Lam T. H., Abdullah A. S., Chan S. S., Hedley A. J. ; Hong Kong Council on Smoking and Health Smoking Cessation Health Centre (SCHC) Steering Group (2005). Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: A preliminary investigation. Psychopharmacology, 177 400–408 doi:10.1007/s00213-004-1971-y
    1. Lee J- H, Herzog T. A., Meade C. D., Webb M. S., Brandon T. H. (2007). The use of GEE for analyzing longitudinal binomial data: A primer using data from a tobacco intervention. Addictive Behaviors, 32 187–193 doi:10.1016/j.addbeh.2006.03.030
    1. Liang K. Y., Zeger S. L. (1986). Longitudinal data analysis using generalizing linear models. Biometrika, 73 13–22 doi:10.1093/biomet/73.1.13
    1. Lichtenstein E., Zhu S. H., Tedeschi G. J. (2010). Smoking cessation quitlines: An underrecognized intervention success story. The American Psychologist, 65 252–261 doi:10.1037/a0018598
    1. Loh W. Y., Piper M. E., Schlam T. R., Fiore M. C., Smith S. S., Jorenby D. E., Baker T. B. (2012). Should all smokers use combination smoking cessation pharmacotherapy? Using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. Nicotine & Tobacco Research, 14 131–141 doi:10.1093/ntr/ntr147
    1. McAfee T. A. (2007). Quitlines a tool for research and dissemination of evidence-based cessation practices. American Journal of Preventive Medicine, 33(6 Suppl.)S357–S367 doi:10.1016/j.amepre.2007.09.011
    1. McAfee T. A., Bush T., Deprey T. M., Mahoney L. D., Zbikowski S. M., Fellows J. L., McClure J. B. (2008). Nicotine patches and uninsured quitline callers. A randomized trial of two versus eight weeks. American Journal of Preventive Medicine, 35 103–110 doi:10.1016/j.amepre.2008.04.017
    1. McAfee T., Fellows J., Zbikowski S. M. (2012). Re: Effect of offering different levels of support and free replacement therapy via an English national telephone quitline: Randomised controlled trial. BMJ, 344 e1696doi:10.1136/bmj.e1696 [Rapid Response Letter to the Editor; Retrieved from ; accessed June 14, 2012]
    1. McAfee T., Sofian N. S., Wilson J., Hindmarsh M. (1998). The role of tobacco intervention in population-based health care: A case study. American Journal of Preventive Medicine, 14(3 Suppl.)46–52 doi:10.1016/S0749-3797(97)00051-2
    1. Nelson D. B., Partin M. R., Fu S. S., Joseph A. M., An L. C. (2009). Why assigning ongoing tobacco use is not necessarily a conservative approach to handling missing tobacco cessation outcomes. Nicotine & Tobacco Research, 11 77–83 doi:10.1093/ntr/ntn013
    1. North American Quitline Consortium (NAQC). (2009). Tobacco cessation quitlines: A good investment to save lives, decrease direct medical costs and increase productivity North American Quitline Consortium, 2009 Retrieved from (accessed October 13, 2011)
    1. North American Quitline Consortium (NAQC) (2011). Results from the 2010 NAQC annual survey of quitlines North American Quitline Consortium, 2011 Retrieved from (accessed December 6, 2011)
    1. Ossip D. J., Abrams S. M., Mahoney M. C., Sall D., Cummings K. M. (2009). Adverse effects with use of nicotine replacement therapy among quitline clients. Nicotine & Tobacco Research, 11 408–417 doi:10.1093/ntr/ntp005
    1. Piper M. E., Smith S. S., Schlam T. R., Fiore M. C., Jorenby D. E., Fraser D., & Baker T. B. (2009). A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Archives of General Psychiatry, 66 1253–1262 doi:10.1093/ntr/ntp005
    1. Robins J. M., Rotnitzky A., Zhao L. P. (1995). Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. Journal of the American Statistical Association, 90 106–121 doi: 10.2307/2291134
    1. Schmitz J. M., Sayre S. L., Stotts A. L., Rothfleisch J., Mooney M. E. (2005). Medication compliance during a smoking cessation clinical trial: A brief intervention using MEMS feedback. Journal of Behavioral Medicine, 28 139–147 doi:10.1007/s10865-005-3663-4
    1. Schneider K. L., Hedeker D., Bailey K. C., Cook J. W., Spring B. (2010). A comment on analyzing addictive behaviors over time. Nicotine & Tobacco Research, 12 445–448 doi:10.1093/ntr/ntp213
    1. Shiffman S., Sweeney C. T., Ferguson S. G., Sembower M. A., Gitchell J. G. (2008). Relationship between adherence to daily nicotine patch use and treatment efficacy: Secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clinical Therapeutics, 30 1852–1858 doi:10.1016/j.clinthera.2008.09.016
    1. Smith S. S., McCarthy D. E., Japuntich S. J., Christiansen B., Piper M. E., Jorenby D. E., Jackson T. C. (2009). Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Archives of Internal Medicine, 169 2148–2155 doi:10.1001/archinternmed.2009.426
    1. Smolkowski K., Danaher B. G., Seeley J. R., Kosty D. B., Severson H. H. (2010). Modeling missing binary outcome data in a successful web-based smokeless tobacco cessation program. Addiction, 105 1005–1015 doi:10.1111/j.1360-0443.2009.02896.x
    1. SRNT Subcommittee on Biochemical Verification (2002). Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research, 4 149–159 doi:10.1080/14622200210123581
    1. Stead L. F., Perera R., Bullen C., Mant D., Lancaster T. (2008). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews (Online) Issue 1 CD000146doi: 10.1002/14651858.CD000146.pub3
    1. Stead L. F., Perera R., Lancaster T. (2006). Telephone counselling for smoking cessation. Cochrane Database of Systematic Reviews (Online), Article Number CD002850doi:10.1002/14651858.CD002850.pub2
    1. Walker N., Howe C., Bullen C., Grigg M., Glover M., McRobbie H., Rodgers A. (2011). Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction, 106 1176–1185 doi:10.1111/j.1360-0443.2011.03419.x
    1. Wiggers L. C., Smets E. M., Oort F. J., Storm-Versloot M. N., Vermeulen H., van Loenen L. B., Legemate D. A. (2006). Adherence to nicotine replacement patch therapy in cardiovascular patients. International Journal of Behavioral Medicine, 13 79–88 doi:10.1207/s15327558ijbm1301_10
    1. Zhu S. H., Anderson C. M., Tedeschi G. J., Rosbrook B., Johnson C. E., Byrd M, Gutiérrez-Terrell E. (2002). Evidence of real-world effectiveness of a telephone quitline for smokers. New England Journal of Medicine, 347 1087–1093 doi:10.1056/NEJMsa020660
    1. Zhu S. H., Stretch V., Balabanis M., Rosbrook B., Sadler G., Pierce J. P. (1996). Telephone counseling for smoking cessation: Effects of single-session and multiple-session interventions. Journal of Consulting and Clinical Psychology, 64 202–211 doi:10.1037/0022-006X.64.1.202

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅